These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8769228)

  • 1. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
    Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
    [No Abstract]   [Full Text] [Related]  

  • 2. Changing stable heart transplant recipients from Sandimmune to Neoral.
    Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
    Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
    [No Abstract]   [Full Text] [Related]  

  • 3. Follow-up after conversion to Neoral in stable heart transplant recipients.
    Pethig K; Geiger M; Korn A; Grote M; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2282-4. PubMed ID: 8769226
    [No Abstract]   [Full Text] [Related]  

  • 4. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
    Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
    Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group.
    Grant D; Rochon J; Levy G
    Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
    Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
    [No Abstract]   [Full Text] [Related]  

  • 12. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
    Roth D; Miller J
    Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
    [No Abstract]   [Full Text] [Related]  

  • 13. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
    Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 16. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 18. Interim analysis of study OLN-356: Neoral versus Sandimmune in US primary liver transplant recipients. OLN-356 Principal Investigators.
    Pinson CW; Beauregard-Zollinger L
    Transplant Proc; 1996 Aug; 28(4):2234-6. PubMed ID: 8769209
    [No Abstract]   [Full Text] [Related]  

  • 19. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.